| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | IT | Common Stock | Options Exercise | $467,310 | +5,837 | +70% | $80.06 | 14,234 | 07 May 2021 | Direct | F1 |
| transaction | IT | Common Stock | Disposed to Issuer | $467,532 | -1,998 | -14% | $234.00 | 12,236 | 07 May 2021 | Direct | F2 |
| transaction | IT | Common Stock | Tax liability | $478,062 | -2,043 | -17% | $234.00 | 10,193 | 07 May 2021 | Direct | F3 |
| transaction | IT | Common Stock | Options Exercise | $868,547 | +8,767 | +86% | $99.07 | 18,960 | 07 May 2021 | Direct | F1 |
| transaction | IT | Common Stock | Disposed to Issuer | $868,608 | -3,712 | -20% | $234.00 | 15,248 | 07 May 2021 | Direct | F2 |
| transaction | IT | Common Stock | Tax liability | $629,460 | -2,690 | -18% | $234.00 | 12,558 | 07 May 2021 | Direct | F3 |
| transaction | IT | Common Stock | Sale | $973,674 | -4,161 | -33% | $234.00 | 8,397 | 10 May 2021 | Direct |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | IT | Stock Appreciation Rights | Options Exercise | $0 | -5,837 | -100% | $0.000000* | 0 | 07 May 2021 | Common Stock | 5,837 | $80.06 | Direct | F4 |
| transaction | IT | Stock Appreciation Rights | Options Exercise | $0 | -8,767 | -50% | $0.000000 | 8,768 | 07 May 2021 | Common Stock | 8,767 | $99.07 | Direct | F5 |
| Id | Content |
|---|---|
| F1 | Represents shares acquired upon exercise of SARs. |
| F2 | Represents shares withheld that had an aggregate value, based on the market price on the date of exercise, substantially equal to the aggregate exercise price of the SARs. |
| F3 | Represents shares withheld for the payment of applicable income and payroll withholding taxes. |
| F4 | These SARs were part of an award that became exercisable in four substantially equal annual installments, commencing on February 8, 2017 and are fully exercisable. |
| F5 | These SARs were part of an award that became exercisable in four substantially equal annual installments, commencing on February 6, 2018 and are fully exercisable. |